How are AI and Big Data disrupting drug discovery?

Drug development is costly and uncertain. But artificial intelligence is promising to make this work cheaper, faster and more effective. As a part of HUBweek in Boston, STAT’s Casey Ross will lead an engaging discussion on how the ability to process huge stores of data is enabling drug makers to identify the precise mechanisms of disease, target new therapies to address them, and build more detailed biological profiles of the types of patient who could benefit. Reserve your seat today for the 10/9 event. (Coffee and snacks will be provided.)